skip to content »

Lester and Sue Smith Breast Center

Houston, Texas

The Lester and Sue Smith Breast Center's mission is to improve prevention, diagnosis and treatment of breast disease.
Lester & Sue Smith Breast Center
not shown on screen

Anna Tsimelzon, Ph.D. - Publications

Publications, Books/Chapters, Abstracts

Selected publications:

  • Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFb signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan;119(2):305-14.
  • Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 68(18):7493-7501, 2008. PMID: 18794137 [PDF]
  • Zhang M, Behbod F, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska A, Rosen JM (2008). Identification of tumor-initiating cells in a p53 null mouse model of breast cancer. Cancer Res 68(12): 4674-4682. PMID: 18559513; PMC2459340 [PDF]
  • Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK and Lee AV. (2008) “Insulin-like growth factor I activates gene transcription programs strongly associated with poor breast cancer prognosis.” J Clin Oncol. 26, 4078-4085.
  • Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O'Connell P, Tsimelzon A, Medina D (2008). Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 14(2): 370-378. [PDF]
  • Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M and Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classical estrogen receptor genomic function, Cancer Research. Cancer Research 68, 826-833, February 1, 2008. [PDF]
  • Alten JA, Moran A, Tsimelzon AI, Mastrangelo MA, Hilsenbeck SG, Poli V, Tweardy DJ. Prevention of hypovolemic circulatory collapse by IL-6 activated Stat3. PLoS ONE. 2008 Feb 13;3(2). [PDF]
  • Lee S, Medina D, Tsimelzon A, Mohsin SK, Mao S, Wu Y, Allred DC (2007). Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol 171(1):252-262. [PDF]
  • Redell MS, Tsimelzon A, Hilsenbeck SG, Tweardy DJ (2007). Conditional overexpression of Stat3a in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern . J Leukocyte Biol 82:975-985. [PDF]
  • Behbod F, Xian W, Shaw CA, Hilsenbeck SG, Tsimelzon A, Rosen JM (2006). Transcriptional profiling of mammary gland side population cells. Stem Cells 24:1065-1074.
  • Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'connell P, Chang JC (2006). Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Res Treat 95:229-233. [PDF]
  • Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SA (2006). Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 66:5950-5959. [PDF]
  • Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O'Connell P, Chang JC (2006). Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 12(17):5047-5054. [PDF]
  • Huang S, Podsypanina K, Chen Y, Cai W, Tsimelzon A, Hilsenbeck S, Li Y (2006). Wnt-1 is dominant over Neu in specifying mammary tumor expression profiles (2006). Technol Cancer Res Treat 5(6):565-572.
  • Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MG, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, (2005). Patterns of Resistance and Incomplete Response to Docetaxel by Gene Expression Profiling in Breast Cancer Patients. Journal of Clinical Oncology, Vol. 23, No 6 (February 20), pp. 1169-1177 [Abstract]
  • Jatoi I, Tsimelzon A, Weiss H, Clark GM , Hilsenbeck SG (2005). Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 89:173-178.
  • David G. DeNardo, Hee-Tae Kim, Susan Hilsenbeck, Valerie Cuba, Anna Tsimelzon, and Powel H. Brown. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: Identification of estrogen-induced/activator protein-1-dependent genes. Molecular Endocrinology. 2005 Feb;19(2):362-78. [PDF]
  • Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MG, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O’Connell P. Gene expression profiling predicts therapeutic response to docetaxel (Taxotere™) in breast cancer patients. Lancet 2003.
  • Tsimelzon AI (1990). Analysis of Fractal Properties of Well Log Curves: Application in Petroleum Geology and Geophysics. Bull. National Institute of Scientific and Technical Information, No. 6199-V90, 11 pages [PDF]
  • Tsimelzon AI, Putkaradze LA, Kerimov KM (1989). Analysis of Overpressure Estimation Methods for Deep Wells based on Well Log Data. Azerbaijan Oil Industry, No. 11, p. 11-14.
  • Tsimelzon AI (1987). Express Method of Pressure Gradient Estimation in Overpressure Zones. Bull. National Institute of Scientific and Technical Information, No. 4733-V87, 29 pages.
  • Tsimelzon AI (1985). An Ordinary Statistics Method for Evaluating Reservoir Properties using Well Log Data. Bull. National Institute of Scientific and Technical Information, No. 5318-V85, 9 pages.
  • Tsimelzon AI (1985). Fuzzy Set Based Software and its Application to Lithological Identification. Transactions of Azerbaijan Academy of Sciences, No. 2, p. 127-130.
  • Tsimelzon AI (1984). Identification of Normal Compaction Intervals based on Catastrophe Theory. Azerbaijan Oil Industry, No. 5, p. 15-18.
  • Tsimelzon AI (1983), Modeling the Interrelationships between Geological and Geophysical Parameters in Unfavorable Statistical Conditions. Mathematical Methods of Geological Modeling. Moscow, Nauka Publishers, p. 26-31.
  • Tsimelzon AI (1980). Statistical Algorithms for the Study of Interrelationships between Geological and Geophysical Parameters. Petroleum Geology and Geophysics, No. 9, p. 50-52.
  • Tsimelzon AI (1980). Resolution of Classification Problems in Petroleum Geology and Geophysics on the Basis of Fuzzy Set Theory, Oil and Gas, No. 8, p. 7-13.
  • Tsimelzon AI (1978). Ridge Regression Application for Modeling Correlation between Physical and Reservoir Properties. Azerbaijan Oil Industry, No. 6, p. 5-7.
  • Tsimelzon AI (1977), Fuzzy Sets Application in Geology and Geophysics. Proceedings of Azerbaijan Institute of Oil and Chemistry. Vol. IX, No. 8, 80-83.

Books/Chapters:

  • Medina D, Kittrell FS, Tsimelzon A, Fuqua SA. Inhibition of mammary tumorigenesis by estrogen and progesterone in genetically engineered mice. Ernst Schering Found Symp Proc. 2007;(1):109-26. In the book: “Progestin and the Mammary Gland: from Basic Sciences to Clinical Applications”.
  • Tsimelzon AI (1986). Comprehensive Computer Interpretation of Geological and Geophysical Information for Oil/Gas Field Exploration, Oil Industry Review, Moscow, VNIIOENG, 52 pages.
  • Akselrod SM, Akinfeyeva GA, Belenkiy VG, Gauzer GE, Gauzer IG, Mamedova EF, Tavrizova EA, Haimov IA, Tsimelzon AI (1977). Computer Interpretation of Well Log Data with PG-2D Software. Manual, Baku, ELM Publishers, 123 p.

Abstracts:

  • Yang WT, Lewis MT, Wong H, Hess K, Tsimelzon A, Karadag N, Cairo M, Meric-Bernstam F, Sahin A, Chang JC. Decreased TGFβ signaling and increased COX2 expression in high risk women with increased mammographic breast density. SABCS Dec 2008, Abstract #1107
  • Covington KR, Barone I, Cui Y, Tsimelzon A, Rodriguez A, Wang T, Fuqua SAW. MTA2 is a metastasis promoter in breast cancer cells. SABCS Dec 2008, Abstract #2047
  • Rodriguez AA, Makris A, Harrison MK, Ostler PJ, Froehlich A, Pavlick A, Wong H, Tsimelzon A, Sexton K, Hilsenbeck SG, Lewis MT, Rimawi M, Osborne CK, Chang JC. BRCA1 gene expression signature predicts for anthracycline-chemosensitivity in triple-negative breast cancer. SABCS Dec 2008, Abstract # 6039
  • W. Yang, A. Sahin, H. Wong, A. Tsimelzon, K. Hess, N. Karadag, M. Cairo, F. Meric, B. Arun, J. C. Chang. Molecular portraits of mammographic breast density in normal breast tissue. ASCO Annual meeting, 2008
  • Fuqua SAW, Beyer, A, Selever J, Hilsenbeck SG, Tsimelzon A, and Cui Y. A unique model of estrogen receptor (ER) a-positive breast cancer metastasis. Abstract for San Antonio Breast Cancer Symposium, Dec. 2007.
  • Selever J, Lewis M, Corona-Rodriguez A, Tsimelzon A, and Fuqua SAW. Tamoxifen resistance and tumor initiation mediated by Dicer overexpression in breast cancer progenitor cells—Role of BCRP. Abstract for San Antonio Breast Cancer Symposium, Dec. 2007.
  • Chad J. Creighton, Suleiman Massarweh, Shixia Huang, Anna Tsimelzon, Susan G. Hilsenbeck, C K. Osborne, Rachel Schiff. Breast tumor xenografts of luminal subtype switch to the ERBB2+ molecular subtype in response to endocrine therapy: gene expression profiling may not predict pathways of resistance in pre-treatment tumors. AACR Molecular Targets conference. October 2007.
  • Chad J. Creighton, Suleiman Massarweh, Anna Tsimelzon, Shixia Huang, Susan G. Hilsenbeck, C K. Osborne, Rachel Schiff. Development of resistance to targeted therapy strategies transforms the clinically-defined molecular profile subtype of breast cancer. . Abstract for San Antonio Breast Cancer Symposium, Dec. 2007.
  • Creighton C, Casa AJ, Lazard ZW, Tsimelzon A; Hilsenbeck SG, Lee AV. Insulin-like growth factor 1 activates gene transcription programs strongly associated with ER- breast cancer and poor patient prognosis. Abstract for San Antonio Breast Cancer Symposium, Dec. 2007.
  • Kaipparettu BA, Hille S, Tsimelzon A. Lee AV, Meyer R, Polo JM,Melnik A, Oesterreich S. The corepressor SAFB in breast cancer – identification of target genes. Abstract for San Antonio Breast Cancer Symposium, Dec. 2007.
  • Kim H-T, Duong S, Li Y, Uray I, Denardo D, Hilsenbeck S, Tsimelzon A, Brown P, Bissonnette R, Lamph W., Johnson K. Discovery of rexinoid-modulated biomarkers in human breast cells using microarrays. Proc of the 47th Annual American Association of Cancer Research, (Abstr 3901), April 1-5, 2006.
  • Redell M, Tsimelzon A, Hilsenbeck SG, Tweardy DJ. Overexpression of Stat3a, but not Statb, in myeloid cells results in neutrophil expansion through reduced apoptosis and modulation of a unique set of apoptosis pathway genes. American Society of Hematology, Orlando, FL, December 9-12, 2006.
  • Cui Y, Zhang M, Parra I, Osborne CK, Hilsenbeck SG, Tsimelzon A, Fuqua SAW. The MAPK inhibitor, MKP3, is an estrogen receptor α coactivator associated with tamoxifen resistance. Proc of the 96th Annual American Association of Cancer Research, (Abstr 4364), April 16-20, 2005.
  • Chang JC, Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Powles T, Wong H, Osborne CK, O'Connell P, Hilsenbeck S. Gene expression arrays for the prediction of response to doxorubicin and cyclophosphamide (AC) in human breast cancers. Proc Am Soc Clin Oncol 23:14s (Abstr 543), 2005.
  • Tsimelzon AI , Susan Cleator, Alan Ashworth, Mitch Dowsett, Timothy Dexter, Trevor Powles, Michael T Lewis, C Kent Osborne, Peter O’Connell, Susan Hilsenbeck, and Jenny C Chang. Gene expression arrays for the prediction of response to Adriamycin and Cytoxan (AC) in human breast cancers. Abstract for Second Annual Cancer Center Symposium, Houston , October, 2004
  • Allred DC, Tsimelzon A, Mohsin SK, Hilsenbeck SG, Medina D, Osborne CK, O’Connell P, Genetic differences between ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res Treat 82(1):214 (Abstr 13), 2003.
  • Chang JCN, Wooten EC, Tsimelzon A, Hilsenbeck SG, Lewis M, Elledge R, Osborne CK, Gutierrez MC, Allred DC, O'Connell PO. Gene expression patterns for de novo and acquired docetaxel resistance in patients with locally advanced breast cancer. Proc Am Soc Clin Oncol 22:32, Abstr 32, 2003.
  • DeNardo DG, Kim HT, Hilsenbeck SG, Tsimelzon A, Brown PH. Identification of estrogen-induced, AP-1-dependent genes by global expression profiling. Proc. Am Association of Cancer Research, v. 44, Abst. 5064, 2003
  • Wooten EC, Chang J, Hilsenbeck SG, Tsimelzon A, Mohsin S. O’Connell P. Gene expression profiles from breast cancer core biopsies predict therapeutic response. Proc Am Assoc Cancer Res 43:450 (abstract 2238), 2002
  • Li Z., Tsimelzon A, Immaneni A, Mohsin SK, Hilsenbeck SG, Clark GC, Fuqua SAW, Osborne CK, O’Connell P, Allred DC, A cDNA microarray study comparing noninvasive and invasive human breast cancer. P. Proc Am Assoc Cancer Res 43: 901-902 (abstract 4471), 2002
  • Gene expression profiles for docetaxel chemosensitivity. J. C. Chang, E. Wooten, R. M. Elledge. S. Hilsenbeck, A. Tsimelzon, S. Mohsin, P. O’Connell. Baylor College of Medicine. Proceedings of American Society of Clinical Oncology 21(1) 426a (#1700) 2002 (abstract), 38th Annual ASCO Meeting. May 18-21, 2002. Orlando, Fl.
  • Li Z., Tsimelzon A, Immaneni A, Mohsin SK, Hilsenbeck SG, Clark GC, Fuqua SAW, Osborne CK, O’Connell P, and Allred DC, Genetic differences between noninvasive and invasive breast cancer by cDNA expression arrays. Breast Center, Baylor College of Medicine. Mod Pathol 15(1) 41A (#231) 2002 (abstract). 91st Annual Meeting of United States and Canadian Academy of Pathology, Feb. 23 - March 1. 2002.
  • Li Z., Tsimelzon AI, Immaneni A, Mohsin SK, Hilsenbeck SG, Clark GC, Fuqua SAW, Osborne CK, O’Connell P, and Allred DC Genetic alteration in the progression of noninvasive breast cancer., Breast Center, Baylor College of Medicine. For 24th Annual San Antonio Breast Cancer Symposium, Dec. 10-13, 2001.
  • Immaneni A, Tsimelzon A, Hilsenbeck SG, Clark GC, Osborne CK, Allred DC, and O’Connell P. Gene expression profiles or recurrence risk in node-negative breast cancers., Breast Center and Departments of Medicine, Molecular and Cellular Biology and Pathology, Baylor College of Medicine. For 24th Annual San Antonio Breast Cancer Symposium, Dec. 10-13, 2001.

E-mail this page to a friend